These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 201375)

  • 21. An experimental model for evaluation of factors in tumor escape from immunological attack.
    Yutoku M; Fuji H; Grossberg AL; Pressman D
    Cancer Res; 1975 Mar; 35(3):734-9. PubMed ID: 1116132
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Importance of the B7-2 molecule for low dose melphalan-induced acquisition of tumor-eradicating immunity by mice bearing a large MOPC-315 tumor.
    Mokyr MB; Kalinichenko TV; Gorelik L; Bluestone JA
    J Immunol; 1998 Feb; 160(4):1866-74. PubMed ID: 9469448
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Importance of Lyt-2+ T-cells in the resistance of melphalan-cured MOPC-315 tumor bearers to a challenge with MOPC-315 tumor cells.
    Barker E; Mokyr MB
    Cancer Res; 1988 Sep; 48(17):4834-42. PubMed ID: 3261626
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Importance of timing in cyclophosphamide therapy of MOPC-315 tumor-bearing mice.
    Hengst JC; Mokyr MB; Dray S
    Cancer Res; 1980 Jul; 40(7):2135-41. PubMed ID: 6446379
    [No Abstract]   [Full Text] [Related]  

  • 25. Melphalan-induced enhancement of antitumor immune reactivity in thymocytes of adult BALB/c mice bearing a large MOPC-315 tumor.
    Bartik MM; Takesue BY; Mokyr MB
    Cancer Res; 1987 Sep; 47(18):4848-55. PubMed ID: 3497711
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cooperation between staphylococcal enterotoxin B and low dose melphalan in the cure of mice bearing a large MOPC-315 tumor and extensive metastases.
    Rubin M; Bluestone JA; Newell KA; Prokhorova A; Mokyr MB
    J Immunol; 1994 Apr; 152(7):3522-9. PubMed ID: 8144932
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Release of immunosuppressive factor(s) by MOPC-315 murine plasmacytoma cells: a possible mechanism of defence.
    Bomstein Y; Ophir R; Harshemes H; Ben-Efraim S
    Anticancer Res; 1993; 13(6A):2125-9. PubMed ID: 8297124
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Importance of Lyt 2+ T-cells in the curative effectiveness of a low dose of melphalan for mice bearing a large MOPC-315 tumor.
    Mokyr MB; Barker E; Weiskirch LM; Takesue BY; Pyle JM
    Cancer Res; 1989 Aug; 49(16):4597-606. PubMed ID: 2568174
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antibody against the antigen receptor of a plasmacytoma prolongs survival of mice bearing the tumor.
    Beatty PG; Kim BS; Rowley DA; Coppleson LW
    J Immunol; 1976 May; 116(5):1391-6. PubMed ID: 1270800
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Induction by cyclophosphamide administration of two distinct anti-tumor effector cells at tumor site and spleen of mice transplanted with MOPC-104E plasmacytoma.
    Nio Y; Ohgaki K; Tobe T
    J Clin Lab Immunol; 1989 May; 29(1):37-43. PubMed ID: 2534133
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Importance of the concomitant presence of palpable MOPC-315 tumor in stimulation of splenocytes by C-type MOPC-315 virus in vitro.
    Schwarzbard Z; Ophir R; Gotlieb-Stematsky T; Benefraim S
    Eur J Cancer Clin Oncol; 1985 Sep; 21(9):1069-75. PubMed ID: 2998801
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunocompetence status as related to growth progression of mouse MOPC-315 plasmacytoma.
    Rashid G; Ophir R; Pecht M; Ben-Efraim S
    In Vivo; 1989; 3(4):279-84. PubMed ID: 2535271
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of TEPC-183 plasmacytoma on resistance of passively or actively immunized BALB/c mice to infection with Streptococcus pneumoniae.
    Havas HF; Schiffman G; Schmitz J
    Cancer Res; 1984 Aug; 44(8):3299-302. PubMed ID: 6744264
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunization of BALB/c mice with recombinant simian virus 40 large tumor antigen induces antibody-dependent cell-mediated cytotoxicity against simian virus 40-transformed cells. An antibody-based mechanism for tumor immunity.
    Bright RK; Shearer MH; Kennedy RC
    J Immunol; 1994 Sep; 153(5):2064-71. PubMed ID: 8051411
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Regulation of immune responses aginst the syngeneic ADJ-PC-5 plasmacytoma in BALB-c mice. III. Induction of specific T suppressor cells to the BALB/c plasmacytoma ADJ-PC-5 during early stages of tumorigenesis.
    Haubeck HD; Kölsch E
    Immunology; 1982 Nov; 47(3):503-10. PubMed ID: 6215340
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effectiveness of low-dose melphalan treatment against a nonimmunogenic primary induced mouse plasmacytoma.
    Ophir R; Pick AI; Ben-Efraim S
    Anticancer Res; 1987; 7(1):91-6. PubMed ID: 3566188
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Role of antitumor immunity in cyclophosphamide-induced rejection of subcutaneous nonpalpable MOPC-315 tumors.
    Mokyr MB; Hengst JC; Dray S
    Cancer Res; 1982 Mar; 42(3):974-9. PubMed ID: 6977410
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Preparation and properties of an antiplasma cell serum directed against a defined plasmacytoma cell population.
    Proctor ML; Herscowitz HB
    J Immunol; 1975 Dec; 115(6):1642-9. PubMed ID: 1184969
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Induction of protective antitumor immune response against a murine plasmacytoma not curable by alkylating-drug treatment.
    Ophir R; Jackman A; Relyveld EH; Ben-Efraim S
    Anticancer Res; 1990; 10(1):231-5. PubMed ID: 2334133
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Secondary in vitro lymphocyte-proliferative responses to syngeneic plasma cell tumors.
    Boyer PJ; Fahey JL
    Cancer Res; 1976 Apr; 36(4):1492-8. PubMed ID: 1083290
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.